BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35232398)

  • 1. Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.
    Zeronian MR; Doulkeridou S; van Bergen En Henegouwen PMP; Janssen BJC
    BMC Mol Cell Biol; 2022 Mar; 23(1):12. PubMed ID: 35232398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.
    Schmitz KR; Bagchi A; Roovers RC; van Bergen en Henegouwen PM; Ferguson KM
    Structure; 2013 Jul; 21(7):1214-24. PubMed ID: 23791944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
    Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
    Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
    Nevoltris D; Lombard B; Dupuis E; Mathis G; Chames P; Baty D
    ACS Nano; 2015 Feb; 9(2):1388-99. PubMed ID: 25603171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescently tagged nanobodies and NanoBRET to study ligand-binding and agonist-induced conformational changes of full-length EGFR expressed in living cells.
    Comez D; Glenn J; Anbuhl SM; Heukers R; Smit MJ; Hill SJ; Kilpatrick LE
    Front Immunol; 2022; 13():1006718. PubMed ID: 36505413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of V
    King MT; Huh I; Shenai A; Brooks TM; Brooks CL
    J Biol Chem; 2018 Aug; 293(35):13626-13635. PubMed ID: 29976754
    [No Abstract]   [Full Text] [Related]  

  • 9. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
    Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
    Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A camelid nanobody against EGFR was easily obtained through refolding of inclusion body expressed in Escherichia coli.
    Xu L; Song X; Jia L
    Biotechnol Appl Biochem; 2017 Nov; 64(6):895-901. PubMed ID: 28853185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of EGFR by a novel multivalent nanobody-liposome platform.
    Oliveira S; Schiffelers RM; van der Veeken J; van der Meel R; Vongpromek R; van Bergen En Henegouwen PM; Storm G; Roovers RC
    J Control Release; 2010 Jul; 145(2):165-75. PubMed ID: 20362020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
    Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
    Chang C; Takayanagi A; Yoshida T; Shimizu N
    Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobody binding to a conserved epitope promotes norovirus particle disassembly.
    Koromyslova AD; Hansman GS
    J Virol; 2015 Mar; 89(5):2718-30. PubMed ID: 25520510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
    Xi X; Sun W; Su H; Zhang X; Sun F
    Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic analysis of allosteric and non-allosteric effects arising from nanobody binding to two epitopes of the dihydrofolate reductase of Escherichia coli.
    Oyen D; Wechselberger R; Srinivasan V; Steyaert J; Barlow JN
    Biochim Biophys Acta; 2013 Oct; 1834(10):2147-57. PubMed ID: 23911607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.
    Omidfar K; Amjad Zanjani FS; Hagh AG; Azizi MD; Rasouli SJ; Kashanian S
    Mol Biol Rep; 2013 Dec; 40(12):6737-45. PubMed ID: 24052234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies.
    Zavrtanik U; Lukan J; Loris R; Lah J; Hadži S
    J Mol Biol; 2018 Oct; 430(21):4369-4386. PubMed ID: 30205092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
    Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
    Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotoxins and nanobody-based immunotoxins: review and update.
    Khirehgesh MR; Sharifi J; Safari F; Akbari B
    J Drug Target; 2021 Sep; 29(8):848-862. PubMed ID: 33615933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.